

# NHS Grampian Formulary Group Decisions for SMC advice published April to May 2024



This document summarises the decisions of the NHS Grampian Formulary Group for Scottish Medicines Consortium (SMC) advice published April to May 2024.

For the latest Formulary Group decisions see the [Grampian Area Formulary website](#).

## May 2024

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](#)

NHS Grampian Formulary Group Decisions for SMC advice published April to May 2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Bevespi Aerosphere® 7.2micrograms/5micrograms pressurised inhalation, suspension (glycopyrronium/formoterol fumarate)	<a href="#">2652</a>	As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	Not routinely available as there is a local preference for alternative medicines	16/04/2024
daridorexant 25mg, 50mg film-coated tablets (Quviviq®)	<a href="#">2611</a>	Treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning. <b>SMC restriction:</b> in patients who have failed cognitive behavioural therapy for insomnia (CBT-I) or for whom CBT-I is unsuitable or unavailable.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024
dostarlimab 500mg concentrate for solution for infusion (Jemperli®)	<a href="#">2635</a>	In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024
mavacamten 2.5mg, 5mg, 10mg, 15mg hard capsules (Camzyos®)	<a href="#">2618</a>	Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024
mirikizumab 100mg solution for injection in pre-filled pen, 300mg concentrate for solution for infusion (Omvo®)	<a href="#">2650</a>	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
remdesivir 100mg powder for concentrate for solution for infusion (Veklury®)	<a href="#">2550</a>	Treatment of COVID-19 in: <ul style="list-style-type: none"> <li>• adults and paediatric patients (at least 4 weeks of age and weighing at least 3kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)</li> <li>• adults and paediatric patients (weighing at least 40kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19</li> </ul> <b>SMC restriction:</b> as an option for treating COVID-19 in hospitals in: <ul style="list-style-type: none"> <li>• adults only if they have a high risk of serious illness (risk factors as defined in section 5 of NICE’s technology appraisal of nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19).</li> <li>• babies, children and young people, only if they:               <ul style="list-style-type: none"> <li>- are aged 4 weeks to 17 years and weigh at least 3kg, and have pneumonia and need supplemental oxygen, or</li> <li>- weigh at least 40kg and have a high risk of serious illness (risk factors as defined in section 5 of NICE’s technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19)</li> </ul> </li> </ul>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/05/2024
ritlicitinib tosylate 50mg hard capsules (Litfulo®)	<a href="#">2610</a>	For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024

NHS Grampian Formulary Group Decisions for SMC advice published April to May 2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
ruxolitinib 15mg/g cream (Opzelura®)	<a href="#">2634</a>	For the treatment of non-segmental vitiligo (NSV) with facial involvement in adults and adolescents from 12 years of age.	Not routinely available as not recommended for use in NHS Scotland, SMC 2634 <a href="https://www.scottishmedicines.org.uk/media/8317/ruxolitinib-topical-opzelura-final-april-2024-amended-080524-for-website.pdf">https://www.scottishmedicines.org.uk/media/8317/ruxolitinib-topical-opzelura-final-april-2024-amended-080524-for-website.pdf</a>	21/05/2024
Symbicort® Turbohaler® 200micrograms/ 6micrograms/ inhalation, inhalation powder	<a href="#">2622</a>	As reliever therapy for adults and adolescents (12 years and older) with mild asthma. <b>SMC restriction:</b> for use in patients who would otherwise receive low dose inhaled corticosteroid (ICS) maintenance therapy plus short-acting beta-2 adrenoceptor agonist (SABA) as needed.	Routinely available in line with local guidance	21/05/2024
tirzepatide 2.5mg, 5mg, 7.5mg, 10mg, 12,5mg, 15mg solution for injection in pre-filled pen (Mounjaro®)	<a href="#">2633</a>	For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications - in addition to other medicinal products for the treatment of diabetes. <b>SMC restriction:</b> in addition to other oral anti-diabetic medicines as an option when glucagon-like peptide-1 (GLP-1) receptor agonists would be considered.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/04/2024
tixagevimab 150mg/mL plus cilgavimab 150mg/mL solution for injection (Evusheld®)	<a href="#">2558</a>	Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.	Not routinely available as not recommended for use in NHS Scotland, NICE TA971 <a href="https://www.nice.org.uk/guidance/TA971">https://www.nice.org.uk/guidance/TA971</a>	21/05/2024

NHS Grampian Formulary Group Decisions for SMC advice published April to May 2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
zanubrutinib 80mg hard capsules (Brukinsa®)	<a href="#">2671</a>	In combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.	Not routinely available as not recommended for use in NHS Scotland, SMC 2671 <a href="https://www.scottishmedicines.org.uk/media/8312/zanubrutinib-brukinsa-non-sub-final-april-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8312/zanubrutinib-brukinsa-non-sub-final-april-2024-for-website.pdf</a>	21/05/2024